Duopharma Biotech Bhd (7148) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Duopharma Biotech Bhd MYR 1.86, price MYR 1.16, upside +60.3%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Duopharma Biotech Bhd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 0.9753 MYR – 2.23 MYR · fair‑value band 1.11 MYR – 2.41 MYR · the 1.16 MYR price screens below the 1.86 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Duopharma Biotech Bhd in your weekly email
Every Wednesday you see whether Duopharma Biotech Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally.
Show more
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under the Eye Glo brand name; antacids under the Alucid brand name; joint pain products under the Donna brand name; skincare products under Dermoplex brand name; cosmeceuticals under the IRORO Nutreatment brand name; and functional food under the CHAMPS Nutribar and PROVITON STR Powerz brand names. The company also provides generic drugs for various therapeutic areas, such as cardiovascular, dermatology, hormonal, respiratory, sensory and nervous system, musculoskeletal, anti-infectives, and others; and specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables for the treatment of diabetes, cancer, cardiovascular, renal, and other diseases. In addition, it engages in the development of small molecules and biologic therapies for the treatment of Alzheimer's disease; digital therapeutics; and stem cell therapies. Further, the company is involved in property management and services; and distribution of chemical products. It exports its products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. Duopharma Biotech Berhad was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.
Stock analysis
Duopharma Biotech Bhd (7148) currently trades at 1.16 MYR, while our model-based Fair Value estimate is 1.86 MYR, implying the stock looks roughly 37.6% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 1.91 MYR per share, and 20 of the 26 models we run sit above the 1.16 MYR price.
Bear case: the Dividend Discount group reads lowest at 0.3900 MYR, and 6 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 1.11 MYR (bear) to 2.41 MYR (bull), the price of 1.16 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Duopharma Biotech Bhd reported revenue of 932M MYR in FY2025 versus 639M MYR in FY2021, a compound +9.9%/yr. Reported net income was 87.5M MYR in FY2025, compounding +7.4%/yr from FY2021.
Key figures
Market cap 1.1B MYR (≈ $274M) · P/E ratio 11.6 · P/S ratio 1.09 · EPS (TTM) 0.1000 MYR · Dividend yield 4.0% · Net margin 9.4% · Return on equity 12.6% · Return on assets (EBIT) 7.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 60%, 7148 screens cheaper than that median.
Fair Value models
Bear 1.11 MYRFair Value 1.86 MYRBull 2.41 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0396 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +13.2% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+11.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.5%
Dividend (yield on the price)4.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8% vs 8%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 15%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +8.8% a year for the price and +2.8% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+60% · Top 25%
Profitability
Return on equity (TTM)13% · Above median
Return on assets6% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)18% · Top 25%
Growth and dividend
Revenue growth−6% · Below median
Dividend yield (TTM)4.0% · Top 25%
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Duopharma Biotech Bhd Fair Value". https://www.fairvalue-calculator.com/stock/7148
Frequently asked questions
Is Duopharma Biotech Bhd (7148) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.86 MYR versus a price of 1.16 MYR, about +60% upside (undervalued).
What is the fair value of 7148?
Our model-based fair value for Duopharma Biotech Bhd is 1.86 MYR (as of Sep 24, 2026), built from audited fundamentals. The current price: 1.16 MYR.
What is the quality score of 7148?
Duopharma Biotech Bhd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Duopharma Biotech Bhd (7148)?
Our model-based price target is the fair value of 1.86 MYR (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 1.11 MYR, optimistic scenario 2.41 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Duopharma Biotech Bhd stock forecast for 2026?
Our models put fair value at 1.86 MYR, about +60% upside versus a price of 1.16 MYR (undervalued). Cautious scenario 1.11 MYR, optimistic scenario 2.41 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Duopharma Biotech Bhd (7148)?
Duopharma Biotech Bhd reported trailing-twelve-month revenue of about 917M MYR (latest available figure, as of Sep 24, 2026).
Does Duopharma Biotech Bhd pay a dividend?
Duopharma Biotech Bhd currently shows a dividend yield of about 3.97% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Duopharma Biotech Bhd (7148)?
For today's price to be fair in a discounted-cash-flow model, Duopharma Biotech Bhd would have to grow free cash flow by +11.0 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 7148 use?
Our models discount Duopharma Biotech Bhd at 12.6 %: a base by market capitalisation (micro), damped by beta 0.36, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Duopharma Biotech Bhd that is +11.0 % per year a year over ten years, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Duopharma Biotech Bhd (7148) delivered so far?
Over the past 5 years revenue at Duopharma Biotech Bhd grew +10.3 % a year. The price currently implies +11.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Duopharma Biotech Bhd (7148) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Duopharma Biotech Bhd (+11.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Duopharma Biotech Bhd (7148)?
The free-cash-flow yield on the price is 7.70 %: that much free cash flow Duopharma Biotech Bhd produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Duopharma Biotech Bhd (7148)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Duopharma Biotech Bhd it is 1.86 MYR per share (as of Sep 24, 2026), against a price of 1.16 MYR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Duopharma Biotech Bhd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 7148 trades below its calculated fair value: price 1.16 MYR, fair value 1.86 MYR, a gap of about +60% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7148?
No. The price is what the market pays today (1.16 MYR); the fair value is what the company's own numbers justify (1.86 MYR). For Duopharma Biotech Bhd the two are 0.7000 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Duopharma Biotech Bhd worth?
The market values Duopharma Biotech Bhd at about 1.1B MYR (market capitalisation, as of Sep 24, 2026). Per share that is 1.16 MYR; our models calculate a fair value of 1.86 MYR per share.
What do the bullish and bearish scenarios say about 7148?
Our models span a range for Duopharma Biotech Bhd: cautious scenario 1.11 MYR, base 1.86 MYR, optimistic 2.41 MYR per share (as of Sep 24, 2026, price 1.16 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7148?
Duopharma Biotech Bhd trades at a price-to-earnings ratio of 11.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.86 MYR is built from several models across several years. Other multiples: PEG 1.0, P/B 0.4, P/S 0.3, EV/EBITDA 1.9.
What is the PEG ratio of 7148?
The PEG ratio of Duopharma Biotech Bhd is 1.04 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Duopharma Biotech Bhd (7148)?
Balance-sheet figures for Duopharma Biotech Bhd (as of Sep 24, 2026): return on equity 12.6%, debt of 0.46 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 7148 from its 52-week high?
Duopharma Biotech Bhd trades at 1.16 MYR, about 24% below its 52-week high of 1.52 MYR and at the low of 1.16 MYR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.86 MYR is for.
Which stocks are comparable to Duopharma Biotech Bhd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Duopharma Biotech Bhd stock attractive at the current price?
The data as of Sep 24, 2026: price 1.16 MYR, calculated fair value 1.86 MYR (+60%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7148 calculated?
We run Duopharma Biotech Bhd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.86 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Duopharma Biotech Bhd currently trades 60 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Duopharma Biotech Bhd (7148)?
The closing price on Sep 24, 2026 was 1.16 MYR. Our model-based fair value is 1.86 MYR, about +60% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Duopharma Biotech Bhd right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (1.11 MYR to 2.41 MYR) leaves room in how you read the outcome.
Where does the earnings growth of Duopharma Biotech Bhd (7148) come from?
Earnings per share at Duopharma Biotech Bhd grew +5.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.2 %, EBIT margin −3.0 %, tax rate +0.0 %, residual (interest, one-offs) −1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Duopharma Biotech Bhd
How large is the market capitalisation of Duopharma Biotech Bhd (7148)?
The market capitalisation of Duopharma Biotech Bhd is 1.1B MYR (≈ $274M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Duopharma Biotech Bhd (7148)?
The price-to-sales ratio of Duopharma Biotech Bhd is 1.09 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Duopharma Biotech Bhd (7148)?
Earnings per share at Duopharma Biotech Bhd are 0.1000 MYR (price ÷ EPS = P/E 11.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Duopharma Biotech Bhd (7148)?
The dividend yield of Duopharma Biotech Bhd is 4.0% (payout 46.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Duopharma Biotech Bhd (7148)?
The net margin of Duopharma Biotech Bhd is 9.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Duopharma Biotech Bhd (7148)?
The return on equity (ROE) of Duopharma Biotech Bhd is 12.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Duopharma Biotech Bhd (7148)?
On an EBIT basis the return on assets of Duopharma Biotech Bhd is 7.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Duopharma Biotech Bhd (7148)?
The operating margin of Duopharma Biotech Bhd is 17.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Duopharma Biotech Bhd (7148)?
Revenue at Duopharma Biotech Bhd is growing −5.7% versus a year earlier (3y avg +10.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Duopharma Biotech Bhd (7148)?
Earnings per share at Duopharma Biotech Bhd are growing +19.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Duopharma Biotech Bhd (7148) carry?
The net debt of Duopharma Biotech Bhd is 202M MYR (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Duopharma Biotech Bhd in the live analysis
One click puts Duopharma Biotech Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
